Should I buy or sell Phreesia stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phreesia in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PHR shares. View PHR analyst ratings or view top-rated stocks .

What is Phreesia's stock price target for 2024?

13 brokerages have issued 12-month price targets for Phreesia's shares. Their PHR share price targets range from $25.00 to $43.00. On average, they anticipate the company's stock price to reach $34.31 in the next twelve months. This suggests a possible upside of 90.3% from the stock's current price. View analysts price targets for PHR or view top-rated stocks among Wall Street analysts .

How have PHR shares performed in 2023?

Phreesia's stock was trading at $32.36 at the beginning of the year. Since then, PHR shares have decreased by 44.3% and is now trading at $18.03. View the best growth stocks for 2023 here .

When is Phreesia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our PHR earnings forecast .

How were Phreesia's earnings last quarter?

Phreesia, Inc. (NYSE:PHR) posted its earnings results on Wednesday, December, 6th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.10. The business earned $91.62 million during the quarter, compared to the consensus estimate of $89.60 million. Phreesia had a negative trailing twelve-month return on equity of 54.28% and a negative net margin of 42.70%. The firm's revenue was up 25.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.76) earnings per share.

What ETFs hold Phreesia's stock?

ETFs with the largest weight of Phreesia (NYSE:PHR) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC) , Fidelity Digital Health ETF (FDHT) , Fidelity Disruptive Medicine ETF (FMED) and iShares U.S. Healthcare Providers ETF (IHF) and

What is Chaim Indig's approval rating as Phreesia's CEO?

172 employees have rated Phreesia Chief Executive Officer Chaim Indig on Glassdoor.com . Chaim Indig has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Phreesia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phreesia investors own include Fastly (FSLY) , Zscaler (ZS) , Okta (OKTA) , DocuSign (DOCU) , HealthEquity (HQY) , Block (SQ) , Appian (APPN) , Walt Disney (DIS) , Globant (GLOB) and Invitae (NVTA) .

When did Phreesia IPO?

(PHR) raised $127 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 7,800,000 shares at $15.00-$17.62 per share. J.P. Morgan, Wells Fargo Securities, William Blair, Allen & Company and Piper Jaffray served as the underwriters for the IPO.

Who are Phreesia's major shareholders?

Phreesia's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (14.23%), Brown Advisory Inc. (5.86%), Jennison Associates LLC (4.05%), Rock Springs Capital Management LP (3.22%), Riverbridge Partners LLC (1.56%) and Loomis Sayles & Co. L P (1.48%). Insiders that own company stock include Allison C Hoffman, Allison C Hoffman , Amy Beth Vanduyn , Balaji Gandhi, Chaim Indig , Cheryl Pegus, David Linetsky , Edward L Cahill, Edward L Cahill , Evan Roberts , Gillian Munson , Janet Gunzburg, Mark Douglas Smith, Michael J Davidoff, Michael Weintraub , Randy Rasmussen and Thomas Altier. View institutional ownership trends .

How do I buy shares of Phreesia?

Shares of PHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

Phreesia Stock Price, News & Analysis (NYSE:PHR)

$18.03

+0.16 (+0.90%)

(As of 12/8/2023 ET)

Compare

Today's Range: $17.49
▼
$18.25
50-Day Range: $12.40
▼
$18.89
52-Week Range: $12.05
▼
$40.00

Volume: 836,082 shs
Average Volume: 657,913 shs
Market Capitalization: $1.00 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.31

Phreesia MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.85 Rating Score
Upside/Downside: 90.3% Upside
$34.31 Price Target
Short Interest: Healthy
3.69% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.60
Upright™ Environmental Score
News Sentiment: 0.09
Based on 24 Articles This Week
Insider Trading: Selling Shares
$567,877 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.54) to ($1.90) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.85 out of 5 stars

Medical Sector

46th out of 946 stocks

Business Services, Not Elsewhere Classified Industry

8th out of 81 stocks

4.4

Analyst's Opinion

Consensus Rating
Phreesia has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $34.31, Phreesia has a forecasted upside of 90.3% from its current price of $18.03.
Amount of Analyst Coverage
Phreesia has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
3.69% of the outstanding shares of Phreesia have been sold short.
Short Interest Ratio / Days to Cover
Phreesia has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Phreesia has recently decreased by 13.14%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Phreesia does not currently pay a dividend.
Dividend Growth
Phreesia does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Phreesia has received a 60.31% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Patient flow management systems", "Health care management software", and "Personal health record software" products. See details.
Environmental Sustainability
The Environmental Impact score for Phreesia is -0.60.

2.3

News and Social Media Coverage

News Sentiment
Phreesia has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 24 news articles for Phreesia this week, compared to 3 articles on an average week.
Search Interest
1 people have searched for PHR on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Phreesia to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Phreesia insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $567,877.00 in company stock.
Percentage Held by Insiders
Only 5.80% of the stock of Phreesia is held by insiders.
Percentage Held by Institutions
94.37% of the stock of Phreesia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Phreesia are expected to grow in the coming year, from ($2.54) to ($1.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Phreesia is -6.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Phreesia is -6.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Phreesia has a P/B Ratio of 3.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Phreesia Stock (NYSE:PHR)

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Wilmington, Delaware.

PHR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PHR Stock News Headlines

December 8, 2023 | finance.yahoo.com

Phreesia, Inc. (NYSE:PHR) Q3 2024 Earnings Call Transcript

December 8, 2023 | americanbankingnews.com

Phreesia (NYSE:PHR) Given New $30.00 Price Target at KeyCorp

December 9, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

December 8, 2023 | americanbankingnews.com

Phreesia (NYSE:PHR) Given New $25.00 Price Target at Raymond James

December 7, 2023 | seekingalpha.com

Is Phreesia Finally Turning The Corner?

December 7, 2023 | americanbankingnews.com

Phreesia (NYSE:PHR) Price Target Lowered to $29.00 at Needham & Company LLC

December 7, 2023 | americanbankingnews.com

Phreesia (NYSE:PHR) Given New $28.00 Price Target at JMP Securities

December 7, 2023 | americanbankingnews.com

Phreesia (NYSE:PHR) Shares Gap Up on Better-Than-Expected Earnings

December 9, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

December 6, 2023 | markets.businessinsider.com

This Analyst Lowers Phreesia's Price Target Despite Projecting "Plenty Of Opportunity For Upside" - Read Why

December 6, 2023 | businesswire.com

Phreesia Announces Third Quarter Fiscal 2024 Results

December 6, 2023 | marketwatch.com

Phreesia Shares Rise 25% on 3Q Sales Surge, Long-Term Outlook

December 6, 2023 | markets.businessinsider.com

Where Phreesia Stands With Analysts

December 6, 2023 | finance.yahoo.com

Q3 2024 Phreesia Inc Earnings Call

December 5, 2023 | benzinga.com

Recap: Phreesia Q3 Earnings

December 5, 2023 | msn.com

Here's What Key Metrics Tell Us About Phreesia (PHR) Q3 Earnings

December 5, 2023 | msn.com

Phreesia GAAP EPS of -$0.58 beats by $0.10, revenue of $91.62M beats by $1.82M

December 5, 2023 | finance.yahoo.com

Phreesia Inc (PHR) Reports Revenue Growth and Narrowed Net Loss in Q3 Fiscal 2024

December 4, 2023 | msn.com

Phreesia Q3 2024 Earnings Preview

December 4, 2023 | markets.businessinsider.com

Phreesia earnings preview: what Wall Street is expecting

December 4, 2023 | benzinga.com

Earnings Preview For Phreesia

December 1, 2023 | msn.com

Phreesia says PAM measure added to Medicare incentive system

December 1, 2023 | finance.yahoo.com

CMS Includes the Patient Activation Measure in its Merit-Based Incentive Payment System Starting in 2024

November 16, 2023 | finance.yahoo.com

Here’s Why Phreesia (PHR) Declined in Q3

November 11, 2023 | morningstar.com

Phreesia Inc PHR

November 8, 2023 | finance.yahoo.com

Phreesia Achieves HITRUST Risk-Based, 2-Year Certification Demonstrating the Highest Level of Information Protection Assurance

November 6, 2023 | bizjournals.com

Vacancy rates remain high for Triangle office supply

See More Headlines

Receive PHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phreesia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 12/06/2023
Today: 12/08/2023
Fiscal Year End: 1/31/2024
Next Earnings (Estimated): 3/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Business services, not elsewhere classified
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:PHR
CUSIP: N/A
CIK: 1412408
Web: www.phreesia.com
Phone: (888) 654-7473
Fax: 646-607-1776
Employees: 1,546
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $34.31
High Stock Price Target: $43.00
Low Stock Price Target: $25.00
Potential Upside/Downside: +90.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.85
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.86)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-176,150,000.00
Net Margins: -47.75%
Pretax Margin: -47.44%
Return on Equity: -54.52%
Return on Assets: -41.73%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 2.58
Quick Ratio: 2.58

Sales & Book Value

Annual Sales: $280.91 million
Price / Sales: 3.54
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.46 per share
Price / Book: 3.30

Miscellaneous

Outstanding Shares: 55,210,000
Free Float: 52,007,000
Market Cap: $995.44 million
Optionable: Not Optionable
Beta: 0.84

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Chaim Indig (Age 44)
Co-Founder, CEO & Director
Comp: $515k
Mr. Evan Roberts (Age 44)
Co-Founder & COO
Comp: $400k
Mr. Michael J. Davidoff (Age 50)
Senior Vice President of Payer Solutions
Comp: $350k
Mr. David Linetsky (Age 43)
Senior Vice President of Life Sciences
Comp: $551.64k
Mr. Balaji Gandhi (Age 49)
Chief Financial Officer
Ms. Janet M. Gunzburg (Age 57)
VP, Principal Accounting Officer & Controller
Mr. Daniel Nathan (Age 46)
Chief Technology Officer
Ms. Allison C. Hoffman (Age 52)
General Counsel & Secretary
Comp: $418.96k
Ms. Maureen McKinney
Vice President of Corporate Communications
Ms. Kharen Hauck
Vice President of Marketing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PHR Stock Analysis - Frequently Asked Questions

Should I buy or sell Phreesia stock right now?: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phreesia in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PHR shares.
View PHR analyst ratings or view top-rated stocks.
What is Phreesia's stock price target for 2024?: 13 brokerages have issued 12-month price targets for Phreesia's shares. Their PHR share price targets range from $25.00 to $43.00. On average, they anticipate the company's stock price to reach $34.31 in the next twelve months. This suggests a possible upside of 90.3% from the stock's current price.
View analysts price targets for PHR or view top-rated stocks among Wall Street analysts.
How have PHR shares performed in 2023?: Phreesia's stock was trading at $32.36 at the beginning of the year. Since then, PHR shares have decreased by 44.3% and is now trading at $18.03.
View the best growth stocks for 2023 here.
When is Phreesia's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our PHR earnings forecast.
How were Phreesia's earnings last quarter?: Phreesia, Inc. (NYSE:PHR) posted its earnings results on Wednesday, December, 6th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.10. The business earned $91.62 million during the quarter, compared to the consensus estimate of $89.60 million. Phreesia had a negative trailing twelve-month return on equity of 54.28% and a negative net margin of 42.70%. The firm's revenue was up 25.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.76) earnings per share.
What ETFs hold Phreesia's stock?: ETFs with the largest weight of Phreesia (NYSE:PHR) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Fidelity Digital Health ETF (FDHT), Fidelity Disruptive Medicine ETF (FMED) and iShares U.S. Healthcare Providers ETF (IHF) and

What is Chaim Indig's approval rating as Phreesia's CEO?: 172 employees have rated Phreesia Chief Executive Officer Chaim Indig on Glassdoor.com. Chaim Indig has an approval rating of 73% among the company's employees.
What other stocks do shareholders of Phreesia own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Phreesia investors own include Fastly (FSLY), Zscaler (ZS), Okta (OKTA), DocuSign (DOCU), HealthEquity (HQY), Block (SQ), Appian (APPN), Walt Disney (DIS), Globant (GLOB) and Invitae (NVTA).
When did Phreesia IPO?: (PHR) raised $127 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 7,800,000 shares at $15.00-$17.62 per share. J.P. Morgan, Wells Fargo Securities, William Blair, Allen & Company and Piper Jaffray served as the underwriters for the IPO.
Who are Phreesia's major shareholders?: Phreesia's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (14.23%), Brown Advisory Inc. (5.86%), Jennison Associates LLC (4.05%), Rock Springs Capital Management LP (3.22%), Riverbridge Partners LLC (1.56%) and Loomis Sayles & Co. L P (1.48%). Insiders that own company stock include Allison C Hoffman, Allison C Hoffman, Amy Beth Vanduyn, Balaji Gandhi, Chaim Indig, Cheryl Pegus, David Linetsky, Edward L Cahill, Edward L Cahill, Evan Roberts, Gillian Munson, Janet Gunzburg, Mark Douglas Smith, Michael J Davidoff, Michael Weintraub, Randy Rasmussen and Thomas Altier.
View institutional ownership trends.
How do I buy shares of Phreesia?: Shares of PHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:PHR) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Phreesia Stock Price, News & Analysis (NYSE:PHR)

Phreesia MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Phreesia Stock (NYSE:PHR)

PHR Stock Price History

PHR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PHR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™